Genetic Signatures

Genetic Signatures EBIT Margin

The EBIT Margin (Operating Margin) of Genetic Signatures (GSS.AX) as of Oct 28, 2026 is -122.76 %. In the previous year, EBIT Margin (Operating Margin) was -116.23 % — a change of 5.62% (lower).

EBIT Margin

-122.76 %

YoY

5.62%

Last updated:

EBIT Margin (Operating Margin) of Genetic Signatures is 2026 -122.76 % . EBIT Margin (Operating Margin) of Genetic Signatures was 2025 -116.23 % . It decreases by 5.62% lower compared to the previous year.

For Genetic Signatures, the operating (EBIT) margin of -122.8% is down versus 8.4% a few years ago.

The Genetic Signatures EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2019
-51.24 AUD
Jan 1, 2020
-42.88 AUD
Jan 1, 2021
5.50 AUD
Jan 1, 2022
8.38 AUD
Jan 1, 2023
-111.52 AUD
Jan 1, 2024
-228.68 AUD
Jan 1, 2025
-116.23 AUD
Jan 1, 2026
-122.76 AUD
The Genetic Signatures EBIT Margin history
YEAREBIT MarginYoY
-122.76 %+5.62%
-116.23 %-49.17%
-228.68 %+105.05%
-111.52 %-1,431.41%
8.38 %+52.16%
5.50 %-112.84%
-42.88 %-16.31%
-51.24 %-24.70%
-68.05 %-0.69%
-68.52 %-25.36%
-91.80 %-69.17%
-297.78 %+211.69%
-95.54 %+985.84%
-8.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genetic Signatures Stock analysis

What does Genetic Signatures do? Genetic Signatures Ltd. develops real-time PCR based products for infectious disease detection, focusing on the 3base platform technology. The company commercializes its MDx 3base platform, enabling high-volume hospitals and pathology labs to screen for infectious pathogens with high specificity and rapid results. Products under the EasyScreen brand include the EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, and EasyScreen Viral Meningitis Detection Kit, sold into diagnostic and research marketplaces. The firm targets hospitals and pathology laboratories as key buyers of its diagnostic solutions. Its products are designed for routine detection of infectious diseases, with the EasyScreen suite addressing specific pathogen categories like enteric, STI, and viral meningitis. The company focuses on research and commercialization of genetic signature identification for disease detection, leveraging its 3base platform for high-throughput screening. Genetic Signatures Ltd. generates revenue through the sale of its real-time PCR based products under the EasyScreen brand. The MDx 3base platform technology is central to its commercial strategy, providing a solution for rapid, specific pathogen screening in clinical settings. The company's product portfolio includes multiple kits targeting different infectious disease categories, all sold into the diagnostic and research markets. Genetic Signatures is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genetic Signatures stock

EBIT Margin (Operating Margin) of Genetic Signatures is -122.76 % in 2026.

EBIT Margin (Operating Margin) of Genetic Signatures changed from -116.23 % to -122.76 %, representing a 5.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Genetic Signatures since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Genetic Signatures with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Genetic Signatures

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Genetic Signatures